Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

102.400
+1.2001.19%
Volume:15.25M
Turnover:1.56B
Market Cap:178.59B
PE:186.71
High:104.000
Open:101.800
Low:100.600
Close:101.200
52wk High:109.100
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:1.10
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:5.01%
ROA:1.56%
PB:7.91
PE(LYR):186.71
PS:11.74

Loading ...

Movement Alert|Innovent Biologics Rises 3.78% in Regular Trading, Exclusive Licensing Agreement with Spero Therapeutics for Third-Generation Anti-CD40L Antibody

Market Focus
·
Jul 15

Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion

Reuters
·
Jul 14

Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027

THOMSON REUTERS
·
Jul 14

Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China

THOMSON REUTERS
·
Jul 14

Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody

THOMSON REUTERS
·
Jul 14

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

GlobeNewswire
·
Jul 14

Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?

Simply Wall St.
·
Jul 12

Nomura Adjusts Innovent Biologics' Price Target to HK$123.17 From HK$114.64, Keeps at Buy

MT Newswires Live
·
Jul 10

Bank of America Securities Foresees Valuation Re-rating for Chinese Pharma Sector Driven by Active Licensing Deals, Raises Innovent Bio Target to HK$119.2

Stock News
·
Jul 10

Biotech Stocks Surge as New National Essential Drug List Includes Innovative Therapies

Stock News
·
Jul 10

Movement Alert|Innovent Biologics Rises 3.13% in Regular Trading, Zhongtai International Reaffirms Buy Rating with Target Price of HK$134.50

Market Focus
·
Jul 10

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

INNOVENT BIO Issues Approximately 1.88 Million Shares Under Employee Scheme

Stock News
·
Jul 07

INNOVENT BIO Issues 38.87k New Shares in June; Public Float Remains Compliant

Bulletin Express
·
Jul 07

Innovent Biologics Files HKEX Next-day Return, Share Capital Rises by 1,882,334 Shares

Reuters
·
Jul 07

Movement Alert|Innovent Biologics Falls 3.04% in Regular Trading, Trading at HKD 87.9

Market Focus
·
Jul 07

Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization

Stock News
·
Jul 06